
Article:
Waspe, J., Chico, T.J.A. orcid.org/0000-0002-7458-5481 and Hansen, T.G. (2021) Applying the adverse outcome pathway concept to questions in anaesthetic neurotoxicity. British Journal of Anaesthesia, 126 (6). pp. 1097-1102. ISSN 0007-0912

https://doi.org/10.1016/j.bja.2021.03.009

Applying the Adverse Outcome Pathway concept to questions in anaesthetic neurotoxicity.

Jennifer Waspe[1*], Timothy J. A. Chico[1], Tom G. Hansen[2,3]

[1] Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Medical School, Beech Hill Road, Sheffield, S10 2RX United Kingdom.

[2] Department of Anaesthesia and Intensive Care, University Hospital Odense, Odense, Denmark

[3] University of Southern Denmark, Department of Clinical Research, Odense, Denmark

*Corresponding author email: J.waspe@sheffield.ac.uk

Keywords: Anaesthesia, neurotoxicity, adverse outcome pathway, toxicity pathway, NMDAR antagonist, GABA agonist

Summary

Introduction

Adverse Outcome Pathways (AOPs) aim to improve research synthesis through structured, multilevel integration of basic science and data from human trials.[1] The AOP approach is endorsed by the Organisation for Economic Co-operation and Development (OECD)[1] and used by toxicologists to aid evidence synthesis in the face of an ever-increasing volume of highly specialised biomedical data.

The AOP concept gained acceptance in regulatory toxicology following a landmark report from the National Academy of Sciences in 2007[2], which recognised that existing practices were insufficient for effective and timely risk assessment of chemicals, due to the rapidly expanding chemical industry. [2, 3, 4] The central tenet of the proposed strategy to improve risk assessments was to develop *toxicity pathways:* a process of delineating the sequence of key events at different biological levels (molecular, cellular, tissue and organ) resulting from chemical perturbation of a biological process or system.[2] The AOP concept evolved from this, broadening the approach to include effects at the level of an organism or population.[5, 6]

So far, AOPs have been developed to address endpoints relevant to chemicals regulation and safety. However, the approach has far wider application than within toxicology. The systematic organisation and appraisal of biomedical data at the core of AOP development echoes methods of literature analysis which are already central to clinical research, but do not encompass mechanistic data. Adoption of the AOP framework as a complement to systematic review and meta-analysis would significantly aid integration of pre-clinical and clinical datasets.

There are particular advantages in applying an agnostic, science-based strategy such as AOPs in anaesthetic research, specifically in paediatric neurotoxicity. In 2017, conclusions drawn about the safety of anaesthesia in children under three years old instigated regulatory involvement from the US Food and Drug Administration.[7] Ultimately, a warning was issued, highlighting concerns that the developing brain could be adversely affected by prolonged exposure to anaesthetic drugs. This has since generated contention among experts, as well as international discussion about how to advance research in this complex field.[8]

For a subject area where expert opinion is staunchly divided, the opportunity to display available evidence in a single integrated platform is appealing. Using the AOP framework, knowledge of the current distribution of evidence would be more accessible, enabling transparent data analysis and identification of critical knowledge gaps. It is hoped that this would contribute towards harmonisation of expert opinion, aid future trial design, and in time may also be used to inform regulatory decision making.

Structure of the Adverse Outcome Pathway framework

An AOP provides a clearly accessible, multiscale overview of the known molecular and cellular events linking a biological stressor to an adverse outcome in an individual or population. An example of AOP structure is shown in Figure 1.

The AOP approach was formulated in 2012 by the OECD Extended Advisory Group on Molecular Screening and Toxicogenomics (EAGMST) and is the most readily usable component of the broader AOP Knowledge-Base initiative.[9]

To develop an AOP, relevant literature is used to identify crucial biological events leading to an observed adverse effect. Specific terminology for each event is stipulated,[10] beginning with a *Molecular Initiating Event* (MIE), which describes the primary interaction of a stressor with a biological system at a receptor or molecular level. Subsequent events are termed *Key Events* (KEs) and the final event is the *Adverse Outcome* (AO). The MIE and AO are referred to as anchors of the AOP.

A KE refers to a specific biological object such as an organelle, enzyme or tissue type, which undergoes a measurable process or change in a certain direction which results in impaired or inhibited functioning of the system e.g. “Ionotropic GABA receptor chloride channel conductance, reduced”.[11] As KEs are used to describe a situation where normal biological function is compromised beyond the capacity for homeostatic mechanisms to compensate, a KE is sometimes described as a motif of biological failure.[1] The title of a KE is formulated according to this structure. Measurement of the KE using simple laboratory or other appropriate techniques should be apparent from the title of the KE and briefly described. It is intuitive that an assay measuring intracellular chloride concentration would be required to identify occurrence of the KE in the above example. In addition, reference ranges for expected levels of enzyme activity in the relevant biological compartment would be helpful in defining whether activity was indeed decreased by the exposure.

A structured record of evidence supporting a KE is documented in a *Key Event description.*[10] Every KE must be part of the causal pathway between exposure and adverse outcome rather than simply an effect of a chemical exposure; this is termed *essentiality.* The essentiality of each KE

is substantiated by the evidence contained in the Key Event description and is evaluated according to the following three domains:

1) Current understanding of the basic biological function or role served by the KE

2) A description of established methods for measurement and or detection of the KE

3) Evidence of the specificity of the KE to a certain life stage, species, tissue type or sex; called the *domain of applicability.*

The relationship between each pair of adjacent KEs is also described in a structured format, termed a Key Event Relationship description.[10] This process examines the empirical evidence demonstrating that at sufficient concentration and duration of exposure, cell defense mechanisms and adaptation processes will be overcome, triggering the next KE. There is clear guidance on the configuration of a Key Event Relationship description, which should encompass the following domains:

1) Biological plausibility of the KER - which may be well-established knowledge

2) Experimental evidence that development of the earlier KE leads to the later KE

3) Summary of incongruences or inconsistencies in the experimental evidence in 2)

Data-permitting, it is possible to quantify a KER in terms of dose-response magnitude and whether there is a threshold for a given adverse effect.

Finally, an assessment of confidence in the overall AOP should be undertaken. Predefined criteria for grading the essentiality of each KE as high, moderate or low according to the presence or absence of direct, indirect or contradictory data is provided within OECD guidance.[10] Similarly, a list of defining questions for grading confidence in the biological plausibility and empirical support for each KER is stipulated. Together with modified Bradford Hill criteria,[10] these gradings are used to generate an overall weight of evidence conclusion, which is an accepted approach to evidence appraisal in toxicology.[12]

Important considerations for AOP development

AOPs should be developed in accordance with a number of underlying assumptions.[1] The first of these is that the process is intentionally reductionist; simplifying complex biological processes to focus only on specific events, which, disrupt normal function when perturbed beyond a certain threshold.[1, 5] Secondly, given the intended modular structure of AOPs and the fact there are frequently several KEs at each level of biological organisation, it should be possible for KEs to be integrated into AOP networks. It is widely acknowledged that biological processes do not operate in such a discrete manner as implied by individual, linear AOPs. Over time however, commitment to constructing AOPs in a modular fashion will contribute to an interface which better resembles systems biology.[1, 10, 13] Thirdly, AOPs should be chemically agnostic. This means a given AOP should be generalisable to the effect of any stressor demonstrated to trigger the MIE, rather than a description of the effects of one chemical.[1]

Application of the AOP approach to anaesthetic neurotoxicity

Anaesthetic neurotoxicity provides a good model for demonstrating the use of AOPs in clinical research. Currently, mechanistic understanding of adverse neurodevelopmental effects attributable to undergoing anaesthesia in early life is incomplete.[14, 15] To construct an AOP (or AOPs) for this problem, available literature should be collated using a systematic search strategy, and stratified, for example, according to anaesthetic drug exposure or a specific developmental window. Careful data extraction of the experimental methods and endpoints reported in each article are then used to identify key themes and indicate how the literature is clustered across different levels of biological organisation. In time this builds a profile for the exposure of interest and its mechanistic link to the adverse outcome. A flowchart demonstrating the approach to developing an AOP is shown in Figure 2. For example; collated studies investigating exposure to known NMDAR antagonists might collectively demonstrate clusters of evidence for: NMDAR antagonism, impaired synaptogenesis and worse performance in tests of learning and memory.[16] These three clusters constitute plausible KEs in the AOP *Neurodevelopmental toxicity due to NMDAR antagonism.* The result is a multilevel literature review presented as a dynamic infographic. The next stage in AOP development is to formulate Key Event Relationship descriptions. This involves a second round of systematic retrieval and evaluation of evidence, this time directed towards the link between KEs i.e. a modified systematic review of evidence

that NMDAR antagonism causes impaired synaptogenesis. Identified studies are analysed qualitatively (e.g. for risk of bias) and quantitatively (tabulating exposure dose, duration and interval for all studies). Ideally this would be done using validated tools appropriate to the type of study in question, however, in practice this is difficult to achieve and appropriate tools for every study type are not currently available.

Existing AOPs have examined some molecular level interactions pertinent to anaesthetic drug exposure, including stimulation of ionotropic gamma-aminobutyric acid (GABA) receptors[11] and n-methyl-d-aspartate receptor (NMDAR) antagonism.[17] At the time of writing, the online repository for AOPs contains over fifty KEs and KERs relating to GABA mediated neurotransmission and NMDA receptor action.[18] Details of these AOPs are publicly available online through the AOP wiki.[18] Specifically, there is significant work examining the relationship between NMDAR antagonism during brain growth, and impaired learning and memory in childhood.[17] It is likely that careful consideration of this work could contribute to the paediatric neurotoxicity knowledgebase.

Advantages and disadvantages of the AOP approach

Broadly, advantages of the AOP concept include the ease with which information can be stored, accessed and examined once the basic structure has been built. Although AOP-development is a labour intensive and time-consuming process, the result is a 'living' review.[10] In other words, additional findings that support or refute existing evidence for a KE or KER can be added as the data is identified, meaning AOPs evolve to reflect the scientific progress on a given subject, and are not reliant on the completeness of a single, initial search strategy. In addition, incorporating contradicting data or studies negating a relationship between KEs aids avoidance of publication bias.

An AOP presents known information in a format which is easily accessible to researchers from any scientific discipline. This facilitates close scrutiny of evidence by experts in different fields, ultimately improving the accuracy and understanding of the subject area in question.

Undertaking research for the protection of human health requires a reliable means for determining the adequacy of the evidence base to address a specific regulatory endpoint or health

effect. Therefore, in order for AOPs to be used in the context of regulatory decision making, ultimately there should be a procedure for addressing questions such as: how reliably an AOP predicts toxic endpoints, what level of uncertainty can be tolerated in this specific context and what the level of evidence is.[10] In each case these questions vary depending on the intended application of the AOP. Meeting the requirements of the chemical risk assessment field poses different challenges to those faced in healthcare. As an example, there might be less emphasis on determining an acceptable margin of uncertainty when implementing the AOP concept for hypothesis generation compared to setting regulatory exposure limits. However, if the approach were used to set thresholds for a biomarker to rule a diagnosis in or out, a greater certainty would be required.

In relation to pediatric neurotoxicity, expert opinion acknowledges the pragmatic difficulties and high costs of further observational or interventional human trials aiming to characterise adverse outcomes in children.[19, 20] Such difficulties are attributable to numerous confounding factors and the complex interplay of social factors, school attendance, influence of pain and quantitative analysis of learning and memory, among many others. A recent systematic review examining the heterogeneity of neurocognitive outcomes in studies investigating effects of anaesthesia in children concluded that consistency in these studies is lacking.[21] In the face of such complex issues, it may be justifiable to reflect on the existing wealth of data on this subject, pause further experimentation or clinical trials and explore mechanistic aspects via the AOP framework. Ideally this would direct focus towards elements of e.g. learning or behaviour which are more likely to be functionally impaired,[22] or direct future trials to a specifically vulnerable group in terms of the timing or duration of anaesthetic exposure.

Evidence appraisal in toxicology and clinical research

There is currently no formal procedure for evidence appraisal in the AOP development process. This is in stark contrast to the heavy emphasis on systematic review methodology in clinical research, which has only recently been adopted into chemical risk assessment and toxicology.[23] Although this is a potential weakness of the AOP approach, there are pragmatic difficulties in defining one method for evaluating a combination of *in-vitro, in-silico, in-vivo* or human data which may be relevant to a given KE. Accordingly, knowledge and tools for critically appraising

the suitability of specific aspects of each of these modalities, and interpreting them with respect to the final AO would be necessary. Currently there is no agreed method or single tool to facilitate evaluating all of these study types in sufficient depth, and so far, it relies very much on expert judgement.

Certainly, methods for evaluation of risk of bias and reliability for *in-vitro* and *in-vivo* studies are less established than in clinical research, and this is an area of controversy particularly in chemical risk assessment.[24] This may present an opportunity to advance methods for evidence appraisal across multiple study types, and promote harmonisation of study evaluation in different scientific disciplines.

Another essential component of systematic review is conducting a structured and comprehensive literature search. During the identification of KEs, a review of the existing literature is required to accrue information about the plausible mechanisms and intermediate steps leading to the final adverse effect. As such, it is intuitive that incorporation of a predefined method for identifying relevant studies would be useful. However, owing to the possibility to add new data to an existing AOP framework over time (which is desirable), a comprehensive search is not essential for a first iteration.

Finally, in order to progress the development and implementation of AOPs in clinical research, possible sources of funding should be considered. Given the broad applicability of the AOP approach, and the nature of the work as secondary research, it is logical that organisations involved in method development, critical appraisal and evidence integration would be best suited to support and advance AOP projects. Example organisations may include Cochrane or GRADE,[25] however, at present any such funding remains to be sought.

Future Perspectives

There is a growing perception that the traditional classification of disease is likely to change as mechanistic science advances, resulting in a new disease taxonomy.[26] An example of this is PRECISESADS; an on-going, multi-centre, non-randomised, cross-sectional study across 18 European centres.[27] The aim of this project is to use machine learning and bioinformatics to analyse biological samples from individuals affected by systemic autoimmune diseases. When

complete, the analysis will encompass genetic and OMICs data (epigenomic, transcriptomic and proteomic among others) with a view to reclassifying the cohort according to the underlying mechanics of the disease process, rather than clinical presentation.[27] The AOP concept strongly supports a grassroots approach to molecular disease classification and there are advantages to adopting this in anaesthesia.

Anaesthetic research faces complex questions, including which individuals will suffer from post-operative delirium or cognitive decline and how can these risks be mitigated through our practice. In these cases, an established AOP framework could provide a roadmap of up-to-date, multilevel evidence to guide decision making and support a molecular level profile for each phenomenon. With over 200 Adverse Outcome Pathways under development, it seems likely this approach will be increasingly implemented in the groundwork for future biomedical research, however, the potential value of AOPs in relation to clinical questions is yet to be realised.

Details of authors' contributions

Manuscript conception/writing: JW, TGH

Revision and approval of final manuscript: TGH, TC

Acknowledgements

The authors would like to thanks to Anna Bal-Price from the European Commission, Joint Research Centre (JRC), Ispra, for her support in the preparation of this manuscript.

Declaration of interests

The authors declare that they have no conflicts of interest.

Funding

No specific funding was obtained.

References

1. Villeneuve DL, Crump D, Garcia-Reyero N et al. Adverse Outcome Pathway (AOP) Development I: Strategies and Principles. Toxicol Sci 2014;142(2):312–20
2. National Research Council. *Toxicity Testing in the 21st Century: A Vision and a Strategy*. Washington, DC: The National Academies Press, 2007
3. Ankley GT, Bennett RS, Erickson RJ et al. Adverse outcome pathways: A conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem 2010;29:730–41
4. Krewski D, Acosta D Jr, Andersen M et al. Toxicity testing in the 21st century: A vision and a strategy. J Toxicol Environ Health B Crit Rev 2010;13:51–138
5. Vinken M, Landesmann B, Goumenou M et al. Development of an Adverse Outcome Pathway From Drug-Mediated Bile Salt Export Pump Inhibition to Cholestatic Liver Injury. Toxicol Sci 2013;136(1): 97–106
6. Joint Research Centre of the European Commission. Toxicity Pathways - from concepts to application in chemical safety assessment. JRC 86467 2013. http://publications.jrc.ec.europa.eu/repository/handle/JRC86467 Accessed January 2, 2021
7. FDA Drug Safety Communication. FDA approves label changes for use of general anesthetic and sedation drugs in young children. https://www.fda.gov/Drugs/DrugSafety/ucm554634.htm Accessed February 27, 2021.
8. Disma N, O'Leary JD, Loepke AW et al. Anaesthesia and the developing brain: A way forward for laboratory and clinical research. Paediatr Anesth 2018;28:758-63
9. OECD. Adverse Outcome Pathway Knowledge Base. https://aopkb.oecd.org/index.html Accessed August 1, 2020
10. OECD. "Users' Handbook supplement to the Guidance Document for developing and assessing Adverse Outcome Pathways". *OECD Series on Adverse Outcome Pathways*, No. 1, OECD Publishing, Paris, 2018
11. Gong, P, Perkins EJ. "Adverse Outcome Pathway on binding to the picrotoxin site of ionotropic GABA receptors leading to epileptic seizures in adult brain". *OECD Series on Adverse Outcome Pathways*, No. 11, OECD Publishing, Paris, 2019

12. OECD. Guiding Principles and Key Elements for Establishing a Weight of Evidence for Chemical Assessment, Series on Testing and Assessment No. 311, Environment, Health and Safety Division, Environment Directorate OECD Publishing, Paris, 2019
13. Spinu N, Bal-Price A, Cronin MTD, Enoch SJ, Madden JC, Worth AP. Development and analysis of an adverse outcome pathway network for human neurotoxicity. Arch Toxicol 2019;93(10):2759-72
14. Davidson A. The effect of anaesthesia on the infant brain. Early Hum Dev 2016;102:37-40
15. Davidson AJ, Sun LS. Clinical evidence for any effect of anesthesia on the developing brain. Anesthesiology 2018;128:840-853
16. Bal-Price A, Lien PJ, Keil KP et al. Developing and applying the adverse outcome pathway concept for understanding and predicting neurotoxicity. Neurotoxicology 2017;59:240-55
17. Sachana M, Rolaki A, Bal-Price A. Development of the Adverse Outcome Pathway (AOP): Chronic binding of antagonist to *N*-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities of children. Toxicol Appl Pharmacol 2018;354:153-75
18. AOP-Wiki. AOPWiki. https://aopwiki.org/ Accessed August 1 2020
19. Weiss M, Hansen TG, Engelhardt T. Ensuring safe anaesthesia for neonates, infants and young children: what really matters? Arch Dis Child 2016;101:650-2
20. Hansen TG, Engelhardt T. Long term neurocognitive outcomes following surgery and anaesthesia in early life. Curr Opin Anaesthesiol 2018;31(3):297-301
21. Clausen NG, Kahler S, Hansen TG. Systematic review of the neurocognitive outcomes used in studies of pediatric anaesthesia neurotoxicity. Br J Anaesth 2018;120(6):1255-73
22. Ing C, Jackson WM, Zaccariello MJ et al. Prospectively assessed neurodevelopmental outcomes in studies of anaesthetic neurotoxicity in children: a systematic review and meta analysis. Br J Anaesth 2021;126(2):433-44
23. Whaley P, Halsall C, Agerstrand M, et al. Implementing systematic review techniques in chemical risk assessment: Challenges, opportunities and recommendations. Environ Int 2016;92-93;556-64

24. Hoffmann S, de Vries RBM, Stephens ML et al. A primer on systematic reviews in toxicology. Arch Toxicol 2017;91:2551–7
25. Guyatt G, Oxman AD, Akl EA et al. GRADE Guidelines: 1. Introduction- GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64(4):383-94
26. Kola I, Bell J. A call to reform the taxonomy of human disease. Nat Rev Drug Discov 2011;10(9):641-2
27. Laigle L, Beretta L, Wojick J, et al. AB1372 towards reforming the taxonomy of human disease: the precisesads cross sectional study. Ann Rheum Dis 2018;77:1771-2

Figure legends

Figure 1.



Diagram showing basic structure of an adverse outcome pathway (AOP).

The molecular initiating event is the first anchor. This is an interaction with a chemical, which is sufficient to perturb molecular level homeostatic mechanisms and cause disruption of normal biological function at progressive steps in the pathway i.e. moving up the chain from cellular to tissues to organ level. This can result in the second anchor; an adverse outcome occurring in an organism or population. A toxicity pathway constitutes the early stages in the AOP, encompassing molecular and cellular level perturbations and focused on the induction of toxicity in a biological system.[2, 3]



Figure 2.

Flowchart indicating the basic process for developing an Adverse Outcome Pathway, including aspects of AOP evaluation.